Drug Profile
Melanoma vaccine - AlphaVax/Memorial Sloan-Kettering Cancer Center
Alternative Names: Alphavirus replicon vaccine expressing tyrosinase-related protein 2 antigen- AlphaVax; TRP2 melanoma vaccine - AlphaVaxLatest Information Update: 28 Jan 2023
Price :
$50
*
At a glance
- Originator AlphaVax
- Developer AlphaVax; Memorial Sloan-Kettering Cancer Center
- Class Antineoplastics; Cancer vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Malignant melanoma
Most Recent Events
- 28 Jan 2023 No recent reports of development identified for preclinical development in Malignant-melanoma in USA (Parenteral)
- 18 Jan 2021 Preclinical development is still ongoing for Malignant melanoma in USA (AlphaVax pipeline, January 2021)
- 28 Mar 2019 No recent reports of development identified for preclinical development in Malignant-melanoma(Prevention) in USA (Parenteral)